Histopathological predictor of response to mirikizumab in active ulcerative colitis Successful use of mirikizumab in three patients with active ulcerative colitis was guided by clinical presentation plus high neutrophilic infiltration of the colonic epithelium (Geboes Grade 3.2).

#MedCase - Successful use of #mirikizumab in three patients with active #UlcerativeColitis was guided by clinical presentation plus high neutrophilic infiltration of the colonic epithelium (Geboes Grade 3.2).

👉 buff.ly/X3BPJaA

#GISky #GastroSky

Fecal Microbiota Transplantation for Liver Disease | Docwire News Dr Tapper, Gastro Today Editorial Board Member, shares his insights into the use of fecal microbiota transplantation for liver disease.

Don't miss the commentary from @ebtapper.bsky.social on #FecalMicrobiotaTransplantation for liver disease. Dr Tapper isn't sure that we're ready to "claim victory" with #FMT just yet.
#Hepatology #GISky #LiverSky

Read the full commentary at the link:

Excellent review Evaluating LFT's

🤔Gastro (in Press)

🤔Link to abstract: www.gastrojournal.org/article/S001...

👍Good for teaching materials, or useful quick review.

#IMsky #Medsky #GIsky

Site Network for IBD Trials | Docwire News Laurent Peyrin-Biroulet, MD, PhD, describes the results of a study evaluating use of a site network to improve enrollment for IBD trials.

Professor Laurent Peyrin-Biroulet discusses a study evaluating use of the Iterative Health site network to improve enrollment for #InflammatoryBowelDisease trials. #IBDSky #GISky
📹 Watch the full interview at the link!

www.docwirenews.com/post/improvi...

Study confirms GLP-1 and GIP agonists should be paused prior to elective upper endoscopy Study confirms that continuing GLP-1 or GLP-1/GIP agonists before elective upper endoscopy raises residual gastric volume risk, supporting guidance to pause therapy prior to procedures.

#MedNews - Study confirms that continuing #GLP1 or GLP-1/GIP agonists before elective upper #endoscopy raises residual gastric volume risk, supporting guidance to pause therapy prior to procedures.

Full story 👉 buff.ly/ff1kRev

#GISky

Gastrointestinal cancers in women: The role of sex hormones The relationship between sex hormones and GI cancers in women is complex, with hormones being protective or predisposing. Understanding how hormonal, genetic, and environmental factors interact could…

The relationship between sex hormones and GI cancers in women is complex, with hormones being protective or predisposing.

Understanding how hormonal, genetic, and environmental factors interact could improve #GICancer care for women.

👉 buff.ly/slaXTWA

#GISky #OncSky

Underwater Endoscopic Submucosal Dissection: Tips and Tricks U-ESD provides natural traction and enhanced visualization that aids removal of complex GI lesions. With ongoing refinements in the technique, U-ESD may become the standard in advanced therapeutic…

Underwater-ESD provides natural traction and enhanced visualization that aids removal of complex GI lesions.

With ongoing refinements in the technique, U-ESD may become the standard in advanced therapeutic #endoscopy.

👉 buff.ly/3UasBlk

#GISky

Coming to a pt near you...Alpha-gal

🤔thought was geographically limited..but spreading

🤔Lone star tic leads to sensitivity to sugar molecule in most red meat or dairy products

🤔Reactions 2-10 hr p ingestion can range from urticaria/angioedema to N+V; abd pain

🤔Beware

#GIsky #IMsky #mdsky

Short review of post op ileus (POI), acute colon pseudo-obstruction(ACPO)

🤔POI: review MEDS; labs; ambulation
🤔Enteral feeding of benefit (POI)
🤔? SC methylnaltrexone for ACPO
🤔? prucalopride for POI & ACPO
🤔? value of chewing gum to prevent POI
🤔Does coffee prevent POI?

#Medsky #IMsky #GISky

Risankizumab for Heavily Pretreated CD | Docwire News Real-world data showed 60% of patients with heavily pretreated Crohn’s disease who received risankizumab achieved steroid-free clinical remission by week 12.

In a large real-world study, more than 60% of patients with #CrohnsDisease treated with #risankizumab achieved steroid-free clinical remission by week 12, and through 1 year of treatment.
#Gastroenterology #GISky #inflammatoryBowelDisease #IBDSky

cALD in US: Common; 85% of pts unaware they have it

🤔Compensated ALD in asymptomatic pts.

🤔Weighted preval of cALD in us 2.4%; possible cALD 3.46%

🤔85% unaware (This surprised me)

Another reminder to screen with FIB-4 and/or Elastography

#IMSky #GISky #Medsky

Delivery Route of FMT: Colonic vs Nasogastric | Docwire News Colonic delivery of fecal microbiota transplantation was a more effective route than nasogastric administration for patients with ulcerative colitis.

Colonic delivery of #FecalMicrobiotaTransplantation was a more effective route than nasogastric administration for patients with #UlcerativeColitis.
#Gastroenterology #InflammatoryBowelDisease #IBDSky #GISky #FMT

Add Statins to our Water? Statins associated with lower risk of HCC and Hepatic decompensation in cirrhosis

🤔Umbrella review ( EASL) 168 studies, 10 mil pts

🤔Reduced risk of HCC (HR 0.53)and decompensation
(HR 0.54)

Continue statins in these patients

Food for thought?

#IMsky #GIsky #Medsky

Heading to DDW? 🧠 Save the date! 📆 Come connect at the #pedsgastropsych meet up! Check out the image for details — we’re gathering Sunday, May 3rd from 11am–Noon central. Join us for community, collaboration, and a chance to meet colleagues across GI psych! #DDW2026 #GISKY #PGSIG #Div54 #pedsGI

Please join us on 4/23 for our Research Day on "Advancing #HealthEquity"!

#MedSky #GISky #Gastrosky

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, ph... In individuals with type 2 diabetes inadequately controlled with metformin, orforglipron 12 mg and 36 mg was non-inferior and superior to semaglutide 7 mg and 14 mg with respect to the mean change in ...

Link: www.thelancet.com/journals/lan... #GISky #PedsSky #EMSky #SciSky #GLP

Coffee Barrett's and Gerd

🤔Review/meta-analysis

🤔Coffee associated with marginal 🔼 Gerd, but not Barrett's. "routine avoidance/reduction of coffee intake ...needs further evaluation"

👍Perhaps restrict in pts who identify it as a trigger, or improve with cessation. Not routinely

#medsky #GIsky

Behavioral Interventions for Crohn’s Disease | Docwire News Taryn Lores, PhD, discusses the CATHARSIS trial and the potential benefit of integrating brain-gut behavioral therapy into treatment for patients with Crohn’s disease.

Taryn Lores, PhD, of the Icahn School of Medicine at Mount Sinai, discusses integrating #BehavioralIntervention therapy into treatment for patients with #CrohnsDisease.
#IBDSky #GISky

Tolerability of GLP-1 RAs in IBD | Docwire News For patients with IBD, GLP-1 receptor agonists provided benefits in weight loss and metabolic improvements without exacerbating IBD symptoms.

#GLP1 receptor agonists may be a safe and beneficial option for managing #obesity and metabolic comorbidities for adults with #InflammatoryBowelDisease.
#GISky #IBDSky

Surveillance Burden of Colonoscopy AI Polyp Detection | Docwire News A retrospective analysis suggests that AI polyp detection during colonoscopy may improve adenoma detection but increase colonoscopy burden without long-term benefit.

AI-driven increases in nonadvanced adenoma detection during #Colonoscopy may meaningfully increase surveillance burden with unclear long-term benefit.
#GISky #ColorectalCancer #ArtificialIntelligence

IV vs SC Vedolizumab for IBD | Docwire News While intravenous and subcutaneous vedolizumab had largely similar safety and efficacy for IBD, there were a few key differences in outcomes.

Real-world data presented at #CCCongress26 suggest IV and SC #vedolizumab have similar overall safety and efficacy in IBD, but IV use was linked to higher hospitalization and steroid use (#UlcerativeColitis) and higher shock rates (#CrohnsDisease). #IBDSky #GISky

DBH Inhibitor for Ulcerative Colitis | Docwire News In results from a phase 1b trial, dopamine beta-hydroxylase inhibitor, APL-1401, demonstrated early efficacy signals for patients with moderate-to-severe active ulcerative colitis.

Phase 1b data suggest early efficacy signals for APL-1401, a first-in-class DBH inhibitor, in moderate-to-severe #UlcerativeColitis. Results presented at the #CCCongress26 support further dose evaluation. #GISky #IBDSky

Let's hear it for short sleeves

🤔Long Sleeves cultured. 280 samples. 81% bacterial growth, 20.7% with potential pathogens. Fleece most likely to be contaminated.

No evidence of spread.

Even so lets hear it for "bare below the elbows."

#IMsky #Medsky #GIsky

#GISky #EndoSky #genetherapy #obesity #glp1

CATHARSIS Meets Measures for Continuation | Docwire News With successful randomization, masking, and retention, the CATHARSIS trial has proved it warrants continuation.

Early CATHARSIS trial data presented at #CCCongress26 suggest combining biologics with structured #BrainGut behavioral therapy may improve well-being in moderate-severe #CrohnsDisease. High feasibility, satisfaction, and retention reported. #IBDSky #GISky

Will PPI's ever be vindicated?

🤔Duru in BMJ - No association between PPI and Gastric
Adenocarcinoma.

🤔Ed (see below): Recognizing the conflicting and uncertain evidence base on PPI ...harms, suggest concern about adverse effects alone...not a reason to avoid prescribing.

#IMsky #GIsky #Medsky

Novel G9a-Inhibitor Shows Promise | Docwire News According to data presented at the 2026 Crohn’s and Colitis Congress, ATH-063 showed preliminary potential with a favorable pharmacokinetics profile.

Phase 1 data presented at #CCCongress26 highlight ATH-063, a first-in-class oral G9a inhibitor. In healthy volunteers, it showed favorable PK, no safety signals, and strong FoxP3+ Treg activation—supporting further study in biologics-resistant IBD.

#IBDSky #GISky

GLP-1 RAs and Crohn’s Disease | Docwire News As reported at the 2026 Crohn’s and Colitis Congress, GLP-1 RAs are potentially beneficial as an adjunct to Crohn’s disease management for patients with overweight or obesity.

Real-world data presented at #CCCongress26 suggest #GLP1 RAs may benefit #CrohnsDisease patients with overweight/obesity. #GLP1RA use was linked to lower steroid dependence, fewer hospitalizations, and improved durability of advanced IBD therapy. #IBDSky #GISky

GLP-1RAs for IBD | Docwire News Use of GLP1 receptor agonists was associated with improved inflammatory bowel disease-related outcomes.

Real-world data presented at #CCCongress26 suggest GLP-1 receptor agonists may improve #InflammatoryBowelDisease outcomes. In IBD, #GLP1 RA use was linked to lower steroid use, hospitalizations, surgery, and mortality, supporting further study. #GISky #IBDSky

#OpthoSky #ObSky #PedsSky #NewsSky #GISky #NurseSky